Funding Round For Cambridge Biotech Company Completed
News Nov 14, 2005
Activotec has announced that it has just completed a significant funding round to enable it to accelerate the growth of the company.
The money was raised quickly through a syndicate mainly composed of private high net worth investors, was significantly oversubscribed and had to be scaled back.
Activotec chief executive, Chris Littlewood, commented, "The funds will be invested in further research and development while expanding our current business."
"This will assist us in our dual strategy of creating and licensing technology to drug developers while also quickly growing our custom peptide and synthesiser sales."
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE